Table 2 Comparison of the acute onset and late onset groups.
From: Antithyroid drug-induced leukopenia and G-CSF administration: a long-term cohort study
Leukopenia acute onset group | Leukopenia late onset group | P-value | G-CSF administration acute onset group | G-CSF administration late onset group | P-value | |
|---|---|---|---|---|---|---|
Number of patients | 88 | 80 | P = 0.39 | 19 | 19 | P = 0.35 |
Person-years | 214 | 2353 | 232 | 2111 | ||
Age (years, 95% CI) | 53.1 (49.7 to 56.5) | 55.1 (51.8 to 58.4) | 53.8 (45.1 to 62.5) | 60.4 (56.2 to 64.6) | ||
Sex | ||||||
Female | 65 | 58 | P = 0.86 | 14 | 13 | P = 1.00 |
Male | 23 | 22 | 5 | 6 | ||
Maximum MMI dose | ||||||
≦15 mg | 46 (52.3%*) | 55 (68.8%*) | P < 0.01 | 8 (44.4%*) | 15 (83.3%*) | P < 0.05 |
> 15 mg | 38 (47.7%*) | 18 (31.2%*) | 10 (55.6%*) | 3 (16.7%*) | ||
Maximum PTU dose | ||||||
≦150 mg | 8 (53.3%*) | 9 (50.0%*) | P = 1.00 | 1 (100.0%*) | 2 (100.0%*) | P = 1.00 |
> 150 mg | 7 (46.7%*) | 9 (50.0%*) | 0 (0.0%*) | 0 (0.0%*) | ||
Days to onset | ||||||
Median (days, range) | 29.5 (3–72) | 422 (74–2073) | 43 (9–72) | 648 (101–1981) | ||
